Assertio (ASRT) Competitors $0.67 +0.03 (+5.14%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.68 +0.01 (+1.36%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. TNXP, TVRD, DBVT, CADL, SLRN, IMMP, DSGN, CMPS, ACB, and BTMDShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Tonix Pharmaceuticals (TNXP), Tvardi Therapeutics (TVRD), DBV Technologies (DBVT), Candel Therapeutics (CADL), Acelyrin (SLRN), Prima BioMed (IMMP), Design Therapeutics (DSGN), COMPASS Pathways (CMPS), Aurora Cannabis (ACB), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Its Competitors Tonix Pharmaceuticals Tvardi Therapeutics DBV Technologies Candel Therapeutics Acelyrin Prima BioMed Design Therapeutics COMPASS Pathways Aurora Cannabis biote Tonix Pharmaceuticals (NASDAQ:TNXP) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Does the media prefer TNXP or ASRT? In the previous week, Tonix Pharmaceuticals had 12 more articles in the media than Assertio. MarketBeat recorded 13 mentions for Tonix Pharmaceuticals and 1 mentions for Assertio. Tonix Pharmaceuticals' average media sentiment score of 0.17 beat Assertio's score of -0.03 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TNXP or ASRT more profitable? Assertio has a net margin of -25.72% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Assertio's return on equity of -24.87% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,313.87% -120.96% -101.28% Assertio -25.72%-24.87%-10.87% Which has more volatility & risk, TNXP or ASRT? Tonix Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Do institutionals and insiders hold more shares of TNXP or ASRT? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Assertio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation and earnings, TNXP or ASRT? Assertio has higher revenue and earnings than Tonix Pharmaceuticals. Assertio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M25.65-$130.04M-$1.96 thousand-0.02Assertio$124.96M0.52-$21.58M-$0.32-2.11 Do analysts rate TNXP or ASRT? Tonix Pharmaceuticals currently has a consensus target price of $585.00, suggesting a potential upside of 1,563.35%. Assertio has a consensus target price of $2.75, suggesting a potential upside of 307.53%. Given Tonix Pharmaceuticals' higher possible upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Assertio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAssertio beats Tonix Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.47M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-2.118.8326.1619.90Price / Sales0.52663.86413.33113.66Price / Cash13.07151.5836.1356.90Price / Book0.534.548.055.38Net Income-$21.58M$31.16M$3.15B$248.50M7 Day Performance3.67%-0.40%1.43%2.04%1 Month Performance0.72%6.76%3.62%4.84%1 Year Performance-50.38%1.17%34.92%20.23% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio1.7679 of 5 stars$0.67+5.1%$2.75+307.5%-41.3%$61.47M$124.96M-2.1120TNXPTonix Pharmaceuticals2.7819 of 5 stars$32.79+1.3%$585.00+1,684.1%-52.3%$241.33M$10.09M-0.0250TVRDTvardi TherapeuticsN/A$25.38-1.5%$71.50+181.7%N/A$237.58M$7.14M0.0080High Trading VolumeDBVTDBV Technologies3.7673 of 5 stars$8.56-8.9%$14.75+72.3%+170.1%$234.46M$4.15M-1.7480Analyst RevisionGap DownCADLCandel Therapeutics2.2593 of 5 stars$4.67-1.7%$21.00+349.7%-20.2%$233.97M$120K-3.4960News CoverageAnalyst UpgradeAnalyst RevisionSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135IMMPPrima BioMed1.4647 of 5 stars$1.52-5.0%$7.00+360.5%-9.6%$221.98M$5.14M0.002,021DSGNDesign Therapeutics0.7494 of 5 stars$3.90+4.3%$4.00+2.6%+15.0%$221.40MN/A-3.9440CMPSCOMPASS Pathways1.9832 of 5 stars$2.35-49.2%$17.00+623.4%-43.3%$219.87MN/A-1.18120High Trading VolumeACBAurora Cannabis0.2936 of 5 stars$3.91-4.2%N/A-1.1%$219.78M$246.72M35.551,073BTMDbiote3.4091 of 5 stars$4.01+1.3%$8.00+99.5%-45.2%$219.39M$197.19M6.57194 Related Companies and Tools Related Companies Tonix Pharmaceuticals Competitors Tvardi Therapeutics Competitors DBV Technologies Competitors Candel Therapeutics Competitors Acelyrin Competitors Prima BioMed Competitors Design Therapeutics Competitors COMPASS Pathways Competitors Aurora Cannabis Competitors biote Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
